Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma-Reference-Cited by-同舟云学术

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Published:2024-06-03 Issue: Volume: Page:
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Facon Thierry¹,Dimopoulos Meletios-Athanasios¹,Leleu Xavier P.¹,Beksac Meral¹,Pour Ludek¹,Hájek Roman¹,Liu Zhuogang¹,Minarik Jiri¹,Moreau Philippe¹,Romejko-Jarosinska Joanna¹,Spicka Ivan¹,Vorobyev Vladimir I.¹,Besemer Britta¹,Ishida Tadao¹,Janowski Wojciech¹,Kalayoglu-Besisik Sevgi¹,Parmar Gurdeep¹,Robak Pawel¹,Zamagni Elena¹,Goldschmidt Hartmut¹,Martin Thomas G.¹,Manier Salomon¹,Mohty Mohamad¹,Oprea Corina¹,Brégeault Marie-France¹,Macé Sandrine¹,Berthou Christelle¹,Bregman David¹,Klippel Zandra¹,Orlowski Robert Z.¹

Affiliation:

1. From the Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research...

Funder

Sanofi

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2400712

Reference34 articles.

1. Multiple myeloma current treatment algorithms

2. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

4. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

5. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma;American Journal of Hematology;2024-09-10

2. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma;BMC Cancer;2024-09-09

3. A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China;Cancer Medicine;2024-09

4. Risk‐adapted treatment in multiple myeloma: Does more make it merrier?;British Journal of Haematology;2024-07-27

5. What Does the Phase III ‘IMROZ’ Study Mean for Patients with Multiple Myeloma? An Interview with the Co-authors;EMJ Hematology;2024-07-15